Results 221 to 230 of about 9,559,132 (390)

Funding prospectus 2003 [PDF]

, 2003

core  

Austrian Science Fund (FWF) Publication Cost Data 2020

, 2021
Katharina Rieck
openalex   +2 more sources

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Correction: Dietary patterns of adults in Italy: Results from the third Italian National Food Consumption Survey, INRAN-SCAI. [PDF]

PLoS One
PLOS One Staff.
europepmc   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Development and Psychometric Validation of the Spanish Version of the Experience of Living With Chronic Heart Failure-University of Navarra Scale. [PDF]

Nurs Health Sci
Olano-Lizarraga M, Saracíbar-Razquin M, Zaragoza-Salcedo A, Cobo-Sanchez JL, Pérez-García S, Simón-Ricart A, Ara-Lucea P, Jimeno-San Martín L, Ducay-Eguillor M, De La Torre-Lomas N, Pérez-Herreros J, Moro-Tejedor N, Guerra-Sánchez L, Cambra-Vidart L, Salinas-Urra S, Rodriguez-Blazquez C, Forjaz MJ, Ayala A, Martín-Martín J.   +18 more
europepmc   +1 more source

16 to 18 funding guidance 2010/11: funding rates: version 1 [PDF]

, 2010

core  

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Correction: Case series: Effects of a ketogenic diet on cardiometabolic health in seven outpatients with bipolar disorder. [PDF]

Front Nutr
Schreel L, Bürkle M, Thiem A, von Baehr V, Sauren J, Keferstein G.   +5 more
europepmc   +1 more source

Funding information North East (FINE): training for funding advisors. Final report [PDF]

, 2008
Carrahar, Michelle, Lilley, Sara
core